{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:06:00Z","timestamp":1772640360017,"version":"3.50.1"},"reference-count":9,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels. This report describes improvement in serum magnesium and associated symptoms after initiating SGLT2i therapy in a patient with refractory hypomagnesemia. A 58-year-old woman presented with persistent hypomagnesemia refractory to oral magnesium supplements. She had history of type 2 diabetes mellitus, hypothyroidism, fibromyalgia, and degenerative disk disease. The cause of hypomagnesemia was attributed to excessive renal losses. Laboratory investigations revealed serum magnesium of 1.2\u2005mg\/dL with fractional excretion of magnesium of 8.9%. She was started on empagliflozin 10\u2005mg daily. Within 4 weeks of therapy, her serum magnesium level corrected with symptomatic improvement, which was sustained a few weeks later. Subsequently, her oral magnesium supplements dose was reduced. SGLT2i has been shown to improve magnesium levels in patients with urinary magnesium wasting. Several mechanisms have been postulated, but the exact physiology remains unknown. SGLT2i have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and cardiac mortality in patients with diabetes. In addition, renal and cardiac benefits are also demonstrated in patients without diabetes. This observation demonstrates that SGLT2i can improve the management of patients with otherwise intractable hypomagnesemia.<\/jats:p>","DOI":"10.1210\/jcemcr\/luac018","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T15:20:16Z","timestamp":1669735216000},"source":"Crossref","is-referenced-by-count":6,"title":["Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-5911","authenticated-orcid":false,"given":"Arunava","family":"Saha","sequence":"first","affiliation":[{"name":"PGY2, Internal Medicine, Saint Vincent Hospital , Worcester, MA 01608 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-7694","authenticated-orcid":false,"given":"Abdulkadir","family":"Omer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Medicine, Saint Vincent Hospital , Worcester, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Medicine, Saint Vincent Hospital , Worcester, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"1","key":"2023100215460175300_luac018-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00012.2014","article-title":"Magnesium in man: implications for health and disease","volume":"95","author":"de Baaij","year":"2015","journal-title":"Physiol Rev"},{"issue":"1","key":"2023100215460175300_luac018-B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/db15-1028","article-title":"Hypomagnesemia in type 2 diabetes: a vicious circle?","volume":"65","author":"Gommers","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"2023100215460175300_luac018-B3","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"2023100215460175300_luac018-B4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI115317","article-title":"Intestinal absorption of magnesium from food and supplements","volume":"88","author":"Fine","year":"1991","journal-title":"J Clin Invest"},{"issue":"2","key":"2023100215460175300_luac018-B5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1681\/ASN.2014030293","article-title":"Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome","volume":"26","author":"Blanchard","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2023100215460175300_luac018-B6","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo controlled trials","volume":"33","author":"Toto","year":"2019","journal-title":"J Diabetes Complications"},{"issue":"3","key":"2023100215460175300_luac018-B7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients","volume":"2","author":"Ray","year":"2020","journal-title":"Kidney Med"},{"issue":"2","key":"2023100215460175300_luac018-B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2023100215460175300_luac018-B9","doi-asserted-by":"publisher","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/advance-article-pdf\/doi\/10.1210\/jcemcr\/luac018\/47464412\/luac018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/1\/luac018\/51825115\/luac018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/1\/luac018\/51825115\/luac018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:46:30Z","timestamp":1696261590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luac018\/6855028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,11,29]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luac018","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,11,29]]},"article-number":"luac018"}}